posted
This stock has huge potential, gained some financing for phase II (12 million), was given a 1 million advance, recieved grants for the study of ocytye by VCU in treating the benz for the navy, and is holding fast at a 300% increase.
IP: Logged |
posted
To get a better pulse on this stock, raging bulls message board has some real dedicated investors. I sure would like to see some interest here though. Is Repoman still around?
IP: Logged |
quote:Originally posted by wdcisco: I have been watching this one...Waiting for the dip to .22 .23
Don't wait too long. There should be a confirmation this week or next about the rest of the 12 million. It is holding fast at .29 When it breaks .30 we should get a nice leg up!
IP: Logged |
quote:Originally posted by wdcisco: I just look at the chart...
the chart says it will pullback the next two-three days then up up up again...JMHO.
Very well could be, but you have to consider the announcement of having put 11 million in the bank. That will solidify finances for phase II and III and increase stability and security for a lot of looky lews on the sidelines.
IP: Logged |
Synthetic Blood International, Inc. Announces Filing of Protocol for Phase II-b Oxycyte Clinical Trial COSTA MESA, Calif.--(BUSINESS WIRE)--April 14, 2008--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that it has filed a clinical protocol with the U.S. Food & Drug Administration (FDA) for its planned Phase II-b clinical trial of Oxycyte(R) in Traumatic Brain Injury (TBI) patients. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
The company's planned multi-center, double-blind, placebo-controlled study would enroll up to 300 patients. 200 patients will be allowed for enrollment through a recently approved $1.9 million grant from the United States Department of Defense to M. Ross Bullock, M.D., Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery. Dr. Bullock is the principal investigator for the planned Phase II-b clinical trial. The company plans to do an interim analysis after enrolling 100 patients and then may elect to enroll up to 300.
"Assuming the FDA approves the protocol, our goal is to begin enrolling and treating TBI patients this summer," said company chairman and CEO Chris J. Stern, DBA. "Everyone has worked so hard in getting this protocol done. It is even more exiting that part of this study will be financed by a Department of Defense grant. One of our researchers always says, Oxycyte will bring patients with TBI back to the taxpayer base. We hope to help save as many patients as we possibly can from ending up in a severe state just because they lacked oxygen in tissue after an injury."
About Synthetic Blood International
Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development an oxygen therapeutic/blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Synthetic Blood International, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include predictions about the expected commencement of clinical trials in Traumatic Brain Injury patients and about the potential benefits of Oxycyte. Actual events or results may differ from Synthetic Blood International, Inc.'s expectations. There can be no assurance that the FDA will approve the Phase II-b treatment protocols as submitted, that the clinical trials will commence in the expected time frame or at all, that the required number of patients will be enrolled, that any trials will meet their endpoints, or that Oxycyte or any company product will be approved by the FDA for any indications. Additional information concerning these and other risk factors affecting Synthetic Blood International, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.SYBD.com. Synthetic Blood International, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
posted
range seems to be between .75-80 This week or next week will probably be between $1.00 to $1.45. Great swing opportunities. Take it or leave it, we are going up!
IP: Logged |
posted
Read this if you are feeling unsure about this stock. This is their proxy statement for the upcoming meeting in June. These guys have their ducks all lined up. This stock is going to skyrocket, yahoooooo!
posted
Hard to know. A lot of people are low balling this stock right now. We should be over a buck pretty soon. My thoughts are $1.00 to $1.25 over the next 6 weeks with some nice swing opportunities. Positive interim results I think will be huge.
IP: Logged |
posted
FDA requires more information. Should create a nice drop for anyone interested in getting in on Monday May 19, 2008. Typical FDA crap, but only guarantee's approval in the next 45 days. Stock should drop sigficantly then rise back to current pps. Good luck to anyone who wants to get in.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
![[Mad]](mad.gif)
)
![[BadOne]](graemlins/headbash.gif)
